GraftWorx

GraftWorx has developed a noninvasive remote monitoring solution for fluid management in hemodialysis patients. Our solution will generate $8 billion of value by growing revenue for dialysis providers and creating cost savings for payers. The GraftWorx system has been validated on 115 patients across 3 clinical studies and we expect to receive FDA clearance in late 2019. We have closed a strategic partnership with WL Gore and a clinical partnership with a prospective dialysis customer who manages ~6,000 patients.